Seven Eight Capital, LP Puma Biotechnology, Inc. Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$12.3 - $35.76 $432,123 - $1.26 Million	-35,132 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$20.77 - $42.37 $577,406 - $1.18 Million	-27,800 Reduced 44.17%	35,132 $1.36 Million
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $26,010 - $60,523	1,296 Added 2.1%	62,932 $1.28 Million
Q3 2018 Oct 18, 2018	BUY	$41.2 - $59.85 $2.54 Million - $3.69 Million	61,636 New	61,636 $2.83 Million
Q3 2017 Oct 16, 2017	SELL	$72.0 - $119.75 $994,248 - $1.65 Million	-13,809 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	13,809	13,809 $1.21 Million

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $143M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.